Objective To conduct a cost-effectiveness analysis from payers' perspectives of six
treatments for lower urinary tract symptoms (LUTS) associated with benign prostatic …

Background: Benign prostatic hyperplasia (BPH) is one of the most prevalent and costly
chronic conditions among middle-aged and elderly men. Prostatic urethral lift (PUL) and …

OBJECTIVE To compare the costs and effectiveness of treatments for benign prostatic
hyperplasia (BPH), including watchful waiting, pharmaceuticals (α‐blockers, 5‐α‐reductase …

Background Recently, minimally invasive therapies (MITs), such as water vapor thermal
therapy (WVTT) and prostatic urethral lift (PUL) have become an alternative to surgery or …

Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS)
due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment …

Benign prostatic hyperplasia (BPH) _is one of the most common benign neoplasms in
elderly men in the United States; it has been estimated that the annual costs of caring for …

Abstract Purpose of Review To provide an economic context within which to consider
treatment options for benign prostatic hyperplasia (BPH). To this end, this review provides a …

Introduction Excellent treatment outcomes with long-term durability and few adverse effects
are expectations of treatments for chronic conditions. The long-term cost effectiveness of …

Throughout the past several decades, interest in health care economics has increased as
health care spending has soared—currently in excess of 1.5 trillion dollars and comprising …

Purpose: We critically evaluated the clinical outcomes and cost characteristics of alternative
procedural treatment options for symptomatic benign prostatic hyperplasia. Materials and …